Heart failureValue of Medical Therapy in Patients >80 Years of Age With Heart Failure and Preserved Ejection Fraction
Section snippets
Methods
The study was approved by the internal review board of the medical institution as a subgroup analysis of a larger study of patients of any age with HF and preserved LVEF. In the original study, admission records during a 3-year period were reviewed for patients admitted with the primary diagnosis of HF. Inclusion criteria were echocardiographic evidence of an EF on admission ≥50% and a clinical diagnosis of HF. Patients were excluded for the presence of atrial fibrillation, severe valvular
Results
Baseline clinical characteristics of all patients and patients grouped by survival during five year follow up are listed in Table 1. One hundred forty-two octogenarians fulfilled the inclusion criteria of HF diagnosis with EF ≥50% and were included in data analysis. Mean age was 87 ± 5 years, and 31% were men. Ninety-eight patients died within the 5-year follow-up, and 44 patients survived beyond the 5-year follow-up. Between survivors and patients who died, there were no statistically
Discussion
Validated treatment options for patients with HF and preserved LV systolic function were lacking. Previous studies analyzing medical therapy with digoxin,4 candesartan,5 or perindopril6 did not show a mortality benefit or decrease in hospitalization rate for patients with HF with preserved systolic function. Verapamil may have increased exercise tolerance,7 but has not been shown to decrease mortality or hospitalizations. A new-generation β blocker, nebivolol, may decrease cardiac
References (14)
- et al.
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
Lancet
(2003) - et al.
Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance
Am J Cardiol
(1990) - et al.
Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients > or = 65 years of age with heart failure and preserved left ventricular systolic function
Am J Cardiol
(2008) - et al.
Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis
J Am Coll Cardiol
(2008) - et al.
ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society
Circulation
(2005) - et al.
Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report
Circulation
(2005) - et al.
Rosuvastatin in older patients with systolic heart failure
N Engl J Med
(2007)